Clinics offering ketamine infusions and injections for “treatment-resistant depression” are today claiming 24-48 hours ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...